Wellington Management Group LLP Raises Stake in Celldex Therapeutics, Inc. $CLDX

Wellington Management Group LLP boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 11.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,543,671 shares of the biopharmaceutical company’s stock after buying an additional 983,195 shares during the quarter. Wellington Management Group LLP owned approximately 12.15% of Celldex Therapeutics worth $355,120,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in Celldex Therapeutics in the third quarter worth about $42,000. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter worth approximately $63,000. Kestra Advisory Services LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter worth approximately $98,000. Finally, Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics in the 2nd quarter worth approximately $125,000.

Analyst Ratings Changes

CLDX has been the subject of a number of recent research reports. UBS Group raised their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Barclays increased their price target on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a report on Monday, June 15th. Canaccord Genuity Group lowered their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.08.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $39.12 on Monday. Celldex Therapeutics, Inc. has a 1 year low of $21.71 and a 1 year high of $45.14. The stock’s fifty day moving average price is $38.51 and its two-hundred day moving average price is $33.33. The company has a market cap of $3.07 billion, a P/E ratio of -8.99 and a beta of 0.87.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts expect that Celldex Therapeutics, Inc. will post -4.13 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.